MedTrace Logo

Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

NCT05420727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-06-18

No results posted yet for this study

Summary

To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

Ga-68-PSMA-11 PET/CT

Ga-68-PSMA-11 PET/CT imaging

DRUG

Lu-177-ITG-PSMA-1

Lu-177-ITG-PSMA-1 treatment

Sponsors & Collaborators

  • John O. Prior

    lead OTHER

Principal Investigators

  • John O Prior, PhD MD · Centre Hospitalier Universitaire Vaudois - Lausanne University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2024-04-09
Completion
2024-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05420727 on ClinicalTrials.gov